9,10-二氢-9,10-二羟基苯并(a)芘 | 24909-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芘
• 中文名称: 9,10-二氢-9,10-二羟基苯并(a)芘
• 中文别名: 9,10-二氢苯并[pqr]四芬-9,10-二醇
• 英文名称: 9,10-dihydrodiol-benzopyrene
• 英文别名: 9,10-Dihydroxy-9,10-dihydro-3,4-benzopyrene；9,10-dihydroxy-9,10-dihydro-benzo[a]pyrene；9,10-dihydrodiol-benzo(a)pyrene；9,10-dihydrodiol-benzo[a]pyrene；9,10-Dihydro-9,10-dihydroxybenzo(a)pyrene；9,10-dihydrobenzo[a]pyrene-9,10-diol
• CAS: 24909-09-9
• 化学式: C₂₀H₁₄O₂
• 分子量: 286.33
• InChiKey: GHARBPKRUUKTCI-UHFFFAOYSA-N

物化性质

• 沸点：
  388.69°C (rough estimate)
• 密度：
  1.1197 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2906299090

SDS

反应信息

• 作为产物：
  描述：

  苯并[a]芘 生成 9,10-二氢-9,10-二羟基苯并(a)芘
  参考文献：
  名称：

  CAVALIERI, ERCOLE L.;ROGAN, ELEANOR G.;CREMONESI, PAOLO;DEVANESAN, PRABHA+, BIOCHEM. PHARMACOL., 37,(1988) N 11, C. 2173-2182

  摘要：

  DOI：

文献信息

• Oxidation of Benzo[a]pyrene by Recombinant Human Cytochrome P450 Enzymes
  作者：Eckhart Bauer、Zuyu Guo、Yune-Fang Ueng、L. Chastine Bell、Darryl Zeldin、F. Peter Guengerich

  DOI：10.1021/tx00043a018

  日期：1995.1

  The oxidation of benzo[a]pyrene (B[a]P) was examined using reconstituted systems prepared with recombinant human cytochrome P450 (P450) enzymes 1A1, 1A2, 2C8, 2C10, 2E1, and 3A4 and with microsomes prepared from Saccharomyces cerevisiae expressing recombinant human P450s 2C8, 2C9, and 2C18. Products measured by HPLC included the 3- and 9-phenols, the 4,5-, 7,8-, and 9,10-dihydrodiols (detected in the presence of epoxide hydrolase), and products in the polar fraction eluting immediately after the void volume. The most active enzyme in all reactions was P450 1A1. P450 3A4 and P450 1A2 formed appreciable amounts of several of the products, including the 3-phenol. P450 2C enzymes and P450 2E1 formed relatively low amounts of all B[a]P products. Consideration of these patterns along with knowledge of levels of expression of the P450s in human tissues and previous results with microsomes leads to the conclusion that P450 1A1 should dominate the oxidation of B[a]P in tissues where it is present and inducible. In human liver the level of P450 1A1 is low and P450 3A4, P450 2C subfamily enzymes, and P450 1A2 probably all contribute. Of the human P450s considered here, P450 1A2 was the most active hepatic enzyme forming the 7,8-dihydrodiol. 7,8-Benzoflavone stimulated the oxidation of B[a]P by P450 3A4 and inhibited the oxidations catalyzed by P450 1A2. The extent of inhibition of P450 1A1 was less (than with P450 1A2), probably due to the rapid oxidation of 7,8-benzoflavone by P450 1A1. The major 7,8-benzoflavone product appears to be the 5,6-oxide.
• Multi-stage stem cell carcinogenesis
  申请人：Krtolica Ana

  公开号：US20100162416A1

  公开（公告）日：2010-06-24

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20210254158A1

  公开（公告）日：2021-08-19

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.
• US6204049B1
  申请人：——

  公开号：US6204049B1

  公开（公告）日：2001-03-20
• [EN] MULTI-STAGE STEM CELL CARCINOGENESIS<br/>[FR] CARCINOGENESE DE CELLULES SOUCHES MULTIETAPES
  申请人：STEMLIFELINE INC

  公开号：WO2010037134A2

  公开（公告）日：2010-04-01

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.